Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurodegenerative

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

- PMLiVE

Medical device M&A hit ‘all-time high’ in 2014

Deals last year were led by Medtronic’s acquisition of Covidien

23andMe signs Parkinson’s deal with Genentech

Adds to list of pharma tie-ups for genetic testing firm

- PMLiVE

Patent cliff losses set to cost pharma $65bn by 2019

Lilly, AZ and Otsuka to be hit hard, says GlobalData

- PMLiVE

AZ and Lilly start BACE inhibitor trial in Alzheimer’s

Early trials show promise for the BACE inhibitor AZD3293

GlobalData makes Americas appointment

Sean Hu has 18 years experience in life sciences consulting

- PMLiVE

Pfizer acquires option to license potential Parkinson’s treatment

Medgenesis cuts exclusive deal for its GDNF treatment

- PMLiVE

AZ and Lilly set up BACE camp for Alzheimer’s

Lilly will pay AZ up to $500m in development and regulatory costs

Roche - Basel

Mixed findings for Roche in Alzheimer’s study

Crenezumab misses targets but shows some signs of activity

- PMLiVE

Lundbeck agrees $658m deal to buy Chelsea Therapeutics

Acquisition boosts Danish firm's neurology profile and presence in US

- PMLiVE

GE Healthcare re-launches online neurological campaign

MIND Online aims to improve understanding of conditions such as Alzheimer's disease

- PMLiVE

CHMP backs Piramal’s Alzheimer’s imaging agent

Neuraceq recommended for approval in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links